Viaskin Peanut: Additional Phase II data

Additional data from the double-blind, French Phase II ARACHILD trial in 54 patients aged 5-17 with a confirmed peanut allergy showed that 100 µg Viaskin Peanut patch produced a response, defined as being able to consume >=10-fold the cumulated reactive dose of peanut proteins, in 20% of patients at month 12. Additionally, the response rate was 40% at month 18. A sub-analysis showed that no adolescents aged 12-17 years (n=19) responded at month 6, 12 or 18. In children aged 5-11 years (n=35), response rates were 14.7% at 6 months, 28.1% at 12 months and 66.7% at 18 months. ...